The below example summarizes a use case where ValueGen.AI explores UK NICE HTA reports on hepatocellular carcinoma (HCC) treatments and summarizes relevant information on safety, efficacy, cost-effectiveness, and critiques.
Reports Analyzed: NICE appraisals from the past 5 years, including:
- TA849: Cabozantinib for advanced HCC post-sorafenib
- TA666: Atezolizumab plus Bevacizumab for advanced or unresectable HCC
- TA555: Regorafenib for advanced HCC post-sorafenib
ValueGen.AI accurately extracted the safety profiles (Table 1), efficacy endpoints (Table 2), cost-effectiveness (Table 3) and key critiques (Table 4) insights from the reports. The system can be adapted to specific needs of users and generate outputs in a desired format.
Table 1. AI-extracted Safety Profiles
Table 2. AI-extracted Efficacy Endpoints
Table 3. AI-extracted Cost Effectiveness Summary
Table 4. AI-extracted Key Critiques
